March 2009
Worldwide Biotech;Mar2009, Vol. 21 Issue 3, p8
Trade Publication
This article reports that the Australian Therapeutic Goods Administration (TGA) has granted product approval for a vaccine developed by Intercell AG to prevent Japanese Encephalitis. The approval follows the positive recommendation provided by Australian Drug Evaluation Committee (ADEC) in December 2008. This decision of the Australian authorities represents the first regulatory approval for the drug in any country.


Related Articles

  • Intercell Gearing Up to Launch Phase III Pediatric Ixiaro Trials. Moran, Nuala // BioWorld International;12/30/2009, Vol. 14 Issue 52, p2 

    The article discusses the plans by Intercell AG to conduct two pediatric Phase III trials of its Japanese encephalitis vaccine Ixiaro. The vaccine, comprised of purified and inactivated form of the virus, received approvals from the U.S. Food & Drugs Administration (FDA), the European Medicines...

  • Intercell Gets Stock Boost as FDA Approves Ixiaro. Sheridan, Cormac // BioWorld International;4/1/2009, Vol. 14 Issue 13, p1 

    The article reports that U.S. Food and Drug Administration (FDA) approval of Intercell AG's Japanese Encephalitis Virus (JEV) vaccine Ixiaro resulted to a 10.7% increase in its share price on March 30, 2009. Earlier, a positive opinion from the European Medicines Agency was obtained by the...

  • Intercell Shares Rise on CHMP Positive Opinion for Ixiaro. Sheridan, Cormac // BioWorld International;12/17/2008, Vol. 13 Issue 51, p1 

    The article reports on the 8.5% rise in the stocks of Intercell AG after its lead product, a vaccine against Japanese Encephalitis virus, received positive opinions from the European Medicines Agency and from Australian drug authorities. The company is preparing for a product lunch in both...

  • Biological E's Japanese Encephalitis vaccine prequalified by WHO.  // BioSpectrum;Aug2013, Vol. 11 Issue 8, p10 

    The article reports on the prequalification awarded by the World Health Organization (WHO) for the global use in adults of the Japanese encephalitis vaccine developed by the India-based biopharmaceutical company Biological E (BioE) in partnership with the European biotechnology company Valneva SE.

  • JEEV Infusing life into humanity. Raju, Narasimha // BioSpectrum;Dec2012, Vol. 10 Issue 12, p50 

    The article reports on Biological E, one of the leading Indian vaccine manufacturers, developing treatment for Japanese Encephalitis (JE), a deadly infectious disease and the leading cause of Acute Encephalitis Syndrome (AES). There were more than 8,000 confirmed cases of JE recorded in India in...

  • Intercell Files BLA, MAA For Encephalitis Vaccine. Sheridan, Cormac // BioWorld International;1/2/2008, Vol. 13 Issue 1, p1 

    The article reports on the success of Intercell AG to complete the biologics license application filing for its lead product, a cell-culture-based vaccine against Japanese encephalitis virus (JEV), just before Christmas of 2007. According to Gerd Zettlmeissl, CEO of Intercell, the completion is...

  • Intercell Gets Stock Boost as FDA Approves Ixiaro.  // Bioworld Week;4/6/2009, Vol. 17 Issue 14, p4 

    The article reports that the Food & Drug Administration (FDA) approval of the Japanese Encephalitis Virus (JEV) vaccine Ixiaro boosts the shares in Intercell AG in the U.S. The stock closed at 23.20 euro, increased by 10.7 percent. The company and its distribution partner Novartis AG, are...

  • CDC RECOMMENDATION INCLUDES INTERCELL'S IXIARO VACCINATION.  // Worldwide Biotech;Aug2009, Vol. 21 Issue 8, p4 

    The article announces that the U.S. Centers for Disease Control & Prevention (CDC) Advisory Committee on Immunization Practices updated its Japanese Encephalitis (JE) recommendations and include IXIARO, a JE vaccine from Intercell AG. It reveals why ACIP made significant changes to their...

  • Clinic Roundup.  // BioWorld Today;2/2/2012, Vol. 23 Issue 13, p7 

    The article offers news briefs related to clinical trials by biopharmaceutical companies as of February 2012. AB Science SA presented results from a Phase II study comparing masitinib and Sutent for treating Gleevec-resistant gastrointestinal stromal tumors (GIST). Dendreon Corp. reported data...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics